Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (565)	12/20/1999 10:32:00 PM
From: Arthur Radley	Respond to of 626

I knew what your answer would be...(:>), but wishful thinking and being antsy for the results to arrive, made me ask. As you state, Novartis has too much riding on this trial to jack with the FDA at this stage.

To: Miljenko Zuanic who wrote (565)	12/21/1999 6:52:00 PM
From: Arthur Radley	Read Replies (2) \| Respond to of 626

Miljenko, I took a vaccination shot and went over to Yahoo and found the following...any comments on this article? To all : CeaVac Phase II by: investorMD (42/M) 12/20/99 10:03 pm Msg: 1865 of 1866 I receive BIOWORLD and they had a really good Titan article in the latest issue. Apparently the Phase II CeaVac trial was designed as a Phase III trial with fewer patients. They are still finalizing the expanded study protocol with the FDA and because of this they can't disclose many details about the study. In addition, the Phase II trial is still blinded so they don't have any data but there are no concerns to date regarding any toxicity of the vaccine. The primary endpoint of the trial is survival, along with time of progression, quality of life, safety and immune responses. According to Kennith Foon who co-invented CeaVac "Ceavac is the first and only cancer vaccine to consistently generate immune responses against CEA (carcinoembryonic antigen). We wanted to develop a vaccine that has a better chance of breaking the immune systems tolerance to CEA. The immune system doesn't recognize CEA as foreign so we prepared a mirror image of CEA as an anti-idiotype antibody to confuse the immune system. We have treated over 50 patients to date and the results have been phenominal. In nearly 100 percent of the cases we generated active immunity against CEA." Foon later went on to say that "we've shown that chemotherapy with standard drugs combined with CeaVac does not interfere with the immune response to CeaVac. This Phase III trial combines standard chemotherapy with or without CeaVac in patients with metastatic colorectal cancer." I originally bought into TTP because of my overwhelming optimism regarding Iloperidone, but damn if the entire pipeline isn't winning me over. I may just have to begin to accumulate more shares.